247 related articles for article (PubMed ID: 29154173)
1. Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer.
Criscitiello C; Bagnardi V; Pruneri G; Vingiani A; Esposito A; Rotmensz N; Curigliano G
Eur J Cancer; 2017 Dec; 87():164-171. PubMed ID: 29154173
[TBL] [Abstract][Full Text] [Related]
2. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
Lundgren C; Bendahl PO; Ekholm M; Fernö M; Forsare C; Krüger U; Nordenskjöld B; Stål O; Rydén L
Breast Cancer Res; 2020 Dec; 22(1):140. PubMed ID: 33357231
[TBL] [Abstract][Full Text] [Related]
3. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
4. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
5. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
6. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
[TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
[TBL] [Abstract][Full Text] [Related]
8. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
9. Lumpectomy followed by radiation improves survival in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes compared to mastectomy alone.
Mouabbi JA; Chand M; Asghar IA; Sakhi R; Ockner D; Dul CL; Hadid T; Aref A; Rimawi MF; Hoyos V
Cancer Med; 2021 Jul; 10(14):4790-4795. PubMed ID: 34080777
[TBL] [Abstract][Full Text] [Related]
10. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
Hwang HW; Jung H; Hyeon J; Park YH; Ahn JS; Im YH; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Choi M; Cho SY; Cho EY
Breast Cancer Res Treat; 2019 Jan; 173(2):255-266. PubMed ID: 30324273
[TBL] [Abstract][Full Text] [Related]
11. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.
Ingold Heppner B; Untch M; Denkert C; Pfitzner BM; Lederer B; Schmitt W; Eidtmann H; Fasching PA; Tesch H; Solbach C; Rezai M; Zahm DM; Holms F; Glados M; Krabisch P; Heck E; Ober A; Lorenz P; Diebold K; Habeck JO; Loibl S
Clin Cancer Res; 2016 Dec; 22(23):5747-5754. PubMed ID: 27189162
[TBL] [Abstract][Full Text] [Related]
12. Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting.
Carbognin L; Pilotto S; Nortilli R; Brunelli M; Nottegar A; Sperduti I; Giannarelli D; Bria E; Tortora G
Oncologist; 2016 Mar; 21(3):283-91. PubMed ID: 26865589
[TBL] [Abstract][Full Text] [Related]
13. Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.
Kotoula V; Chatzopoulos K; Lakis S; Alexopoulou Z; Timotheadou E; Zagouri F; Pentheroudakis G; Gogas H; Galani E; Efstratiou I; Zaramboukas T; Koutras A; Aravantinos G; Samantas E; Psyrri A; Kourea H; Bobos M; Papakostas P; Kosmidis P; Pectasides D; Fountzilas G
Oncotarget; 2016 Jan; 7(4):5074-87. PubMed ID: 26506242
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
Hida AI; Sagara Y; Yotsumoto D; Kanemitsu S; Kawano J; Baba S; Rai Y; Oshiro Y; Aogi K; Sagara Y; Ohi Y
Breast Cancer Res Treat; 2016 Jul; 158(1):1-9. PubMed ID: 27260189
[TBL] [Abstract][Full Text] [Related]
15. Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive Breast Cancer.
Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2017 Oct; 37(10):5623-5630. PubMed ID: 28982879
[TBL] [Abstract][Full Text] [Related]
16. Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy.
Montagna E; Vingiani A; Maisonneuve P; Cancello G; Contaldo F; Pruneri G; Colleoni M
Breast; 2017 Aug; 34():83-88. PubMed ID: 28544923
[TBL] [Abstract][Full Text] [Related]
17. Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers.
Lee SJ; Hwang CS; Kim YK; Lee HJ; Ahn SJ; Shin N; Lee JH; Shin DH; Choi KU; Park DY; Lee CH; Huh GY; Sol MY; Lee HJ; Gong G; Kim JY; Kim A
Cancer Res Treat; 2017 Apr; 49(2):313-321. PubMed ID: 27456948
[TBL] [Abstract][Full Text] [Related]
18. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer.
Criscitiello C; Vingiani A; Maisonneuve P; Viale G; Viale G; Curigliano G
Breast Cancer Res Treat; 2020 Sep; 183(2):347-354. PubMed ID: 32621251
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Tumor Infiltrating Lymphocytes in Locally Advanced HER2 Enriched Breast Cancer.
Saber MM; El Zawahry HM; Hilal AM; Abou-Bakr AA; Namour AE; Saber MM
Asian Pac J Cancer Prev; 2022 Feb; 23(2):553-560. PubMed ID: 35225468
[TBL] [Abstract][Full Text] [Related]
20. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
